儿童起病多发性硬化的表观遗传衰老
这项多中心病例对照研究比较了125例儿童起病多发性硬化(POMS)患者与145名年龄相仿对照者的全血DNA表观遗传年龄,采用4种表观遗传时钟算法。调整年龄、性别、BMI、烟草暴露和社会经济地位后,Hannum和PhenoAge时钟显示POMS患者表观遗传年龄加速显著高于对照,提示即使在最年轻的多发性硬化患者中也可能存在加速衰老。
要点
- 儿童起病多发性硬化患者较同龄对照者表现出表观遗传年龄加速。
- Hannum和PhenoAge时钟的年龄加速差异具有统计学显著性。
- 结果支持多发性硬化本身可能驱动早衰的假说。
核心结论
- 儿童起病多发性硬化患者较年龄相仿对照者表观遗传年龄更大、年龄加速更明显,提示加速衰老可能早在最年轻的多发性硬化患者中即已存在。
研究设计与样本
- 多中心病例对照分析,纳入前瞻性收集的全血DNA样本和临床数据,对约850,000个CpG位点计算定量甲基化评分,基于4种既定表观遗传时钟算法计算表观遗传年龄。
- 病例组125例儿童起病多发性硬化患者(平均年龄15.7岁,SD=2.6,女性63.2%),对照组145名年龄相仿对照者(平均年龄15.3岁,SD=3.4,女性63.5%)。
主要发现
- 调整年龄、性别、体重指数、烟草暴露和社会经济地位后,4种表观遗传时钟的点估计均显示病例组表观遗传年龄和年龄加速残差(AAR)大于对照组。
- Hannum时钟β=1.50年(CI=0.58-2.42),p=0.002;PhenoAge时钟β=1.72年(CI=0.09-3.35),p=0.004,差异有统计学意义。
- Horvath时钟β=0.31年(CI=-0.32-0.94),p=0.33;GrimAge时钟β=0.33年(CI=-0.30-0.96),p=0.29,差异无统计学意义。
临床怎么用
- 在儿童起病多发性硬化患者中可考虑将表观遗传年龄作为评估加速衰老的生物学标志物,但当前证据尚不足以指导临床决策。
- 临床关注儿童起病多发性硬化患者的长期衰老相关共病风险,表观遗传时钟的差异提示需进一步研究其预后价值。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Older chronological age is associated with decreased multiple sclerosis (MS) relapse rates and increased risk of progressive disease. Measurement of biological age may be more precise than birthdate in understanding these aging effects. In addition to normal aging, MS-related accelerated aging may contribute. Measurement of biological age in adults may be confounded by the effects of natural aging and age-related comorbidities. Examining age extremes can be informative, and demonstrating accelerated biological aging in children would support a hypothesis of MS driving premature aging. We sought to compare epigenetic age in participants with pediatric-onset MS (POMS) and age-similar controls. METHODS: We performed a multicenter case-control analysis of epigenetic age in a prospectively collected set of whole blood DNA samples and clinical data. Quantitative methylation scores were derived for approximately 850,000 cytosine-phosphate-guanine (CpG) sites. Epigenetic age was calculated based on 4 established epigenetic clock algorithms. Epigenetic age and age acceleration residual (AAR) were compared between participants with POMS and age-similar controls using multivariate regression analysis, adjusted for demographic variables. RESULTS: Epigenetic age and AAR were greater in cases (n = 125, mean age 15.7 years [SD = 2.6], 63.2% female) compared with controls (n = 145, mean age 15.3 years [SD = 3.4], 63.5% female) after adjusting for age, sex, body mass index, tobacco exposure, and socioeconomic status. This difference was statistically significant for 2 of the 4 epigenetic clocks used (Horvath β = 0.31 years [CI = -0.32-0.94], p = 0.33; Hannum β = 1.50 years [CI = 0.58-2.42], p = 0.002; GrimAge β = 0.33 years [CI = -0.30-0.96], p = 0.29; PhenoAge β = 1.72 years [CI = 0.09-3.35], p = 0.004). DISCUSSION: We observed greater point estimates of epigenetic age in participants with POMS compared with healthy controls in all epigenetic clocks tested. This difference was statistically significant for the Hannum and PhenoAge clocks after multivariable modeling. These results are consistent with those of studies in adult MS and suggest that accelerated aging may be present even in the youngest people living with MS.
引用
- Goyne C, Fair AE, Yilmaz D, et al. Epigenetic Aging in Pediatric-Onset Multiple Sclerosis. Neurology. 2025. PMID: 40460354. doi:10.1212/WNL.0000000000213673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。